Department of Otolaryngology, Head and Neck Surgery, New York-Presbyterian Hospital, New York, New York, USA.
Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Surg Oncol. 2021 Oct;124(5):731-739. doi: 10.1002/jso.26598. Epub 2021 Jul 8.
Sinonasal and skull base tumors are rare, making it difficult to identify trends in surgical outcome. This study examines complications in a large cohort of patients undergoing surgery for sinonasal malignancy.
Following IRB approval, an institutional database was reviewed to identify patients who underwent surgery for sinonasal or skull base malignancies from 1973 to 2016 at our institution. Charlson comorbidity index score and Clavien-Dindo grade were calculated. The main study endpoint was subgroup analysis of Clavien-Dindo Grade 0, Grades 1-2, and Grades 3-5 complications. An ordinal logistic regression model was constructed to assess the association between comorbidities, demographics, tumor characteristics, and surgical complications.
In total, 448 patients met inclusion criteria. Perioperative mortality rate at 30 days was 1.6% (n = 7). The rate of severe complications (Clavien-Dindo 3 or higher) was 13.6% (n = 61). Multivariate analysis using an ordinal logistic regression model showed no association between Charlson comorbidity index score and Clavien-Dindo grade of postoperative complication. Advanced T-stage was significantly associated with complications (p = 0.0014; odds ratio: 3.442 [95% confidence interval: 1.615, 7.338]).
Surgery for sinonasal and skull base tumors is safe with a low mortality rate. Advanced T-stage is associated with postoperative complications. These findings have implications for preoperative risk stratification. Key Points Surgery for sinonasal malignancy is safe with a 30 mortality of 1.6% and rate of severe complications of 12.8%. There is no association between patient comorbidity and post operative complication. On multivariate analysis, only advanced T stage was associated with increased rate of surgical complication.
鼻腔鼻窦和颅底肿瘤较为罕见,因此难以确定手术治疗结果的趋势。本研究分析了大量接受鼻腔鼻窦恶性肿瘤手术治疗患者的并发症。
本研究经机构审查委员会批准后,回顾性分析了我院自 1973 年至 2016 年间因鼻腔鼻窦或颅底恶性肿瘤而接受手术的患者的病例资料。计算 Charlson 合并症指数评分和 Clavien-Dindo 分级。主要研究终点为 Clavien-Dindo 0 级、1-2 级和 3-5 级并发症的亚组分析。构建有序逻辑回归模型评估合并症、人口统计学特征、肿瘤特征和手术并发症之间的关联。
共有 448 例患者符合纳入标准。术后 30 天的病死率为 1.6%(n=7)。严重并发症(Clavien-Dindo 分级 3 级或更高)的发生率为 13.6%(n=61)。使用有序逻辑回归模型的多变量分析显示,Charlson 合并症指数评分与术后并发症的 Clavien-Dindo 分级之间无相关性。T 分期较晚与并发症显著相关(p=0.0014;优势比:3.442[95%置信区间:1.615,7.338])。
鼻腔鼻窦和颅底肿瘤的手术治疗是安全的,病死率低,并发症发生率为 12.8%。患者的合并症与术后并发症之间无相关性。多变量分析显示,仅 T 分期较晚与手术并发症发生率增加相关。这些发现对术前风险分层具有重要意义。
鼻腔恶性肿瘤手术治疗的病死率为 1.6%,严重并发症发生率为 12.8%,安全性较高。患者合并症与术后并发症之间无相关性。多变量分析显示,仅 T 分期较晚与手术并发症发生率增加相关。